Regulated information   Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment-services provider to purchase an aggregate number of Ipsen S.A. shares up to 600,000, or about 0.72% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan. This program is made pursuant to the authorization granted by the Company’s Annual General Meeting, held on 21 May 2025. ENDS About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline...

                                                                   WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 pm Geneva, Switzerland – June 2, 2025 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, is proud to announce that it will present Faben’s holograms for the first time at Lisbon NFC. There will be a live performance by Faben as well as a live discussion with WISe.ART Art Director on stage. Since its launch in 2021, WISe.ART, the NFT platform developed by WISeKey, has led numerous high-impact and pioneering NFT projects. Combining trusted digital identity, robust cybersecurity,...

AVTL successfully completed IPO Rotterdam, the Netherlands, 02 June 2025 Today, we announce an update regarding the primary equity issue of our joint venture AVTL. AVTL has successfully completed its IPO. The issue price for the IPO was INR 235 per share which is at the top end of the previously announced price band. The size of the primary equity issue is INR 2,800 crore (approximately EUR 290 million).  The board of AVTL issued an equivalent of 10.75% of new equity shares. As a result of the issuance of new shares, Vopak’s shareholding reduced from 47.31% to 42.23%.  AVTL commenced trading today, Monday 2 June 2025, at the National Stock Exchange of India Limited and BSE Limited.  Dick Richelle, CEO of Royal Vopak: “We are very pleased with the successful realisation of AVTL’s IPO, a significant milestone reflecting the strong...

Press ReleaseVodafone Qatar selects Nokia in major network modernization deal to drive expanded 5G coverage, reliability, and servicesThe deal entails Core modernization, expanded 5G capacity, and enhanced broadband to strengthen network reliability, service offering, and efficiency.2 June 2025Espoo, Finland – Nokia today announced a major agreement with Vodafone Qatar to lead a nationwide network modernization that will enable the operator to deliver faster, more secure, and highly adaptable 5G services to consumers and businesses across the country, while preparing the network for next-generation innovations. In a major expansion of the two companies’ partnership, Vodafone Qatar will leverage Nokia’s end-to-end technology to boost network capacity and reduce latency while accelerating time-to-market with new capabilities and introducing...

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).   The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatment of SBS is based on results from a pivotal Phase 3 trial (EASE-1), supported by interim results from two ongoing long-term extension trials (EASE-2...

2 June 2025 – DNO ASA, the Norwegian oil and gas operator, today announced it has engaged Arctic Securities AS, DNB Carnegie (a part of DNB Bank ASA) and Pareto Securities AS as Joint Bookrunners to arrange fixed income investor meetings. Subject to inter alia market conditions and acceptable terms, a new subordinated hybrid bond issue may follow. – For further information, please contact:Media: media@dno.noInvestors: investor.relations@dno.no – DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Côte d’Ivoire and Yemen. More information is available at www.dno.no. This...

WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET Geneva, Switzerland, June 2, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its management team will be presenting at the Maxim Group 2025 Virtual Tech Conference “Discover the Innovations Reshaping Tomorrow.” WISeKey’s fireside chat presentation is scheduled for June 3rd at 8:30 am ET. Investors can access the live presentation via the following link: https://m-vest.com/events/tmt-06032025. During the presentation, Carlos Moreira, WISeKey’s Founder and CEO, will provide a progress update on WISeKey’s platform as it advances through the “Year of Convergence,” integrating its subsidiaries’ cybersecurity offerings:...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEWYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and cancer-related skeletal events in US and enhances US biosimilar portfolio Builds on established experience and leadership in oncology and immunology biosimilarsBasel, June 2, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, has announced that WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are available to patients in the US starting today. WYOST® and Jubbonti® are the first and only interchangeable FDA-approved denosumab biosimilars and are approved to treat all indications of the reference medicines XGEVA®*...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunologyAdds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolioParis and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint. The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, Blueprint’s established presence among allergists, dermatologists,...